Novartis to fight US price-fixing claims against Sandoz unit
ZURICH: Novartis on Monday said claims of price fixing against its Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.
"We believe that these claims are without merit and will vigorously contest them," Novartis said. "Sandoz takes its obligations under the antitrust laws seriously.
Read Also: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder: Report
We will continue to be committed to providing high-quality, affordable medicines to U.S. patients, and conducting business with customers and the government with integrity."
The 500-page lawsuit, filed by U.S. states on Friday, contends drugmakers conspired to inflate drug prices, sometimes by more than 1,000% or more, as well as stifle competition.
Read Also: Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd